PMID- 21751895
OWN - NLM
STAT- MEDLINE
DCOM- 20111128
LR  - 20161125
IS  - 1205-7541 (Electronic)
IS  - 0008-4212 (Linking)
VI  - 89
IP  - 6
DP  - 2011 Jun
TI  - In-stent restenosis after revascularization of myocardium with drug-eluting 
      stents is accompanied by elevated level of blood plasma eosinophil cationic 
      protein.
PG  - 413-8
LID - 10.1139/y11-038 [doi]
AB  - The aim of this study was to assess the involvement of eosinophil cationic 
      protein, a marker of eosinophil activation, in the development of in-stent 
      restenosis after drug-eluting stent implantation. Follow-up angiography at 6 to 
      12 months was performed in 32 patients who were treated with percutaneous 
      coronary intervention and implantation of sirolimus-eluting stents. Blood plasma 
      levels of eosinophil cationic protein (ECP) and total immunoglobulin E (IgE) were 
      measured by enzyme-linked immunosorbent assay and the level of C-reactive protein 
      (hs-CRP) by high-sensitivity nephelometry. According to angiography data, 
      in-stent restenosis occurred in 13 patients, while 19 patients did not develop 
      it. There were no differences between the hs-CRP and IgE levels in patients with 
      or without restenosis. In contrast, ECP level was higher in patients with 
      restenosis compared with that in patients without restenosis [17.7 ng/mL 
      (11.2-24.0) vs. 9.0 ng/mL (6.4-12.9), p = 0.017]. The incidence of in-stent 
      restenoses was 63% in patients with ECP level higher than or equal to 11 ng/mL, 
      and 19% in patients with an ECP level lower than 11 ng/mL (p = 0.019). These 
      findings suggest that elevated eosinophil activation may play an important role 
      in the pathogenesis of in-stent restenosis after implantation of drug-eluting 
      stents.
FAU - Gabbasov, Zufar A
AU  - Gabbasov ZA
AD  - Cardiology Research Center, 3rd Cherepkovskaya Street, 15A, Moscow, 121 552, 
      Russia. gabbasov@cardio.ru
FAU - Kozlov, Sergei G
AU  - Kozlov SG
FAU - Imaeva, Asiya E
AU  - Imaeva AE
FAU - Saburova, Olga S
AU  - Saburova OS
FAU - Zykov, Kirill A
AU  - Zykov KA
FAU - Masenko, Valery P
AU  - Masenko VP
FAU - Smirnov, Vladimir N
AU  - Smirnov VN
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110713
PL  - Canada
TA  - Can J Physiol Pharmacol
JT  - Canadian journal of physiology and pharmacology
JID - 0372712
RN  - 0 (Biomarkers)
RN  - 0 (Immunosuppressive Agents)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - EC 3.1.27.- (Eosinophil Cationic Protein)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Aged
MH  - Biomarkers/blood
MH  - C-Reactive Protein/analysis
MH  - Coronary Angiography
MH  - Coronary Restenosis/blood/diagnostic imaging/*etiology
MH  - *Drug-Eluting Stents
MH  - Eosinophil Cationic Protein/*blood
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Immunoglobulin E/blood
MH  - Immunosuppressive Agents/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Myocardial Revascularization/*methods
MH  - Sirolimus/*therapeutic use
MH  - Treatment Outcome
EDAT- 2011/07/15 06:00
MHDA- 2011/12/13 00:00
CRDT- 2011/07/15 06:00
PHST- 2011/07/15 06:00 [entrez]
PHST- 2011/07/15 06:00 [pubmed]
PHST- 2011/12/13 00:00 [medline]
AID - 10.1139/y11-038 [doi]
PST - ppublish
SO  - Can J Physiol Pharmacol. 2011 Jun;89(6):413-8. doi: 10.1139/y11-038. Epub 2011 
      Jul 13.